Immunosuppressant Use Mediates Neuroprotection Against Alzheimer's Disease in Rheumatoid Arthritis—A Two‐Step Mendelian Randomization and NHANES Study
International Journal of Rheumatic Diseases · 2026
DOI: 10.1111/1756-185x.70823 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2026. Verfasst von Cong Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Anqing Medical College, Anqing, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Arthritis, Rheumatoid, Immunosuppressive Agents, Cognition. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
Objectives
To investigate whether immunosuppressant (IS) use contributes to the inverse association between rheumatoid arthritis (RA) and Alzheimer's disease (AD).
Methods
We analyzed NHANES 2011–2014 data, including 217 RA patients aged ≥ 60 years on prescription medications. Cognitive function was assessed using the Digit Symbol Substitution Test (DSST), CERAD, Animal Fluency Test (AFT), and a global cognition z ‐score ( Z ‐score). Associations between IS use and cognition were evaluated using multivariable linear regression. Additionally, two‐sample Mendelian randomization (TSMR) and multivariable MR (MVMR) analyses were performed with GWAS datasets for RA, AD, and IS to examine potential causal effects.
Results
We observed that patients with RA using IS performed better in z.DDST ( β : 0.335, p = 0.036) and Z ‐score ( β : 0.214, p = 0.032) after adjusting for covariates, with sex‐specific differences in cognitive domains. TSMR indicated that genetically predicted RA was associated with lower AD risk (OR: 0.936, p = 4.531E−04), and this effect was largely mediated by IS use. MVMR further validated the independent neuroprotective effect of IS on AD (OR = 0.884, p = 0.003) after adjusting for glucocorticoid and NSAID use, while these other medications showed no significant association with AD risk.
Conclusions
These results suggest that the reduced risk of AD observed in RA patients may be partly related to IS use, highlighting a potential role of IS in improving cognitive function and modulating AD risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anqing Medical College, Anqing, China.
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.
- Department of Health Promotion and Behavioral Sciences, School of Public Health, Anhui Medical University, Hefei, China.
ORCID-Profile: Sha-Sha Tao, Hai-Feng Pan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, C., Cheng, J., Yang, M., Li, J. P., Tao, S. S., Wang, P., & Pan, H. F. (2026). Immunosuppressant Use Mediates Neuroprotection Against Alzheimer's Disease in Rheumatoid Arthritis—A Two‐Step Mendelian Randomization and NHANES Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70823
Vancouver
Chen C, Cheng J, Yang M, Li JP, Tao SS, Wang P, et al. Immunosuppressant Use Mediates Neuroprotection Against Alzheimer's Disease in Rheumatoid Arthritis—A Two‐Step Mendelian Randomization and NHANES Study. International Journal of Rheumatic Diseases. 2026. doi:10.1111/1756-185x.70823
BibTeX
@article{Chen2026,
author = {Chen, Cong and Cheng, Jian and Yang, Min and Li, Ji-Ping and Tao, Sha-Sha and Wang, Peng and Pan, Hai-Feng},
title = {Immunosuppressant Use Mediates Neuroprotection Against Alzheimer's Disease in Rheumatoid Arthritis—A Two‐Step Mendelian Randomization and NHANES Study},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
doi = {10.1111/1756-185x.70823}
}
EUVIMED